The Top 5 Biosimilar Articles for the Week of August 25

August 29, 2025

Here are the top 5 biosimilar articles for the week of August 25, 2025.

Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27, 2025

Canadian RWE Shows Comparable Outcomes Between Etanercept Biosimilars, Originator

August 26, 2025

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

August 25, 2025

The Top 5 Biosimilar Articles for the Week of August 18

August 22, 2025

The Top 5 Biosimilar Articles for the Week of February 17

February 21st 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of February 17, 2025.

EC Approves Celltrion Denosumab, Aflibercept Biosimilars

February 20th 2025

By Skylar Jeremias

Article

Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar (Eydenzelt).

FDA, EMA Approve Second Pair of Denosumab Biosimilars

February 17th 2025

By Skylar Jeremias

Article

The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' denosumab biosimilars, which will be marketed under different names depending on whether they will be used to treat osteoporosis or bone metastases.

Teriparatide Biosimilar Shows Comparable Efficacy to Reference Drug in Postmenopausal Osteoporosis

February 17th 2025

By Cameron Santoro

Article

Researchers treated postmenopausal women with osteoporosis with teriparatide biosimilar RGB-10, which improved their bone health measures and reduced fracture risk comparably to reference teriparatide.

FDA Approves First Insulin Aspart Biosimilar

February 17th 2025

By Skylar Jeremias

Article

The FDA approved Merilog (insulin-aspart-szjj) as the first biosimilar to reference Novolog (insulin aspart) for the treatment of adult and pediatric patients with type 2 diabetes.

BioRationality: A Socratic Analysis of IQVIA Report on Biosimilars

February 17th 2025

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, gives his opinion on how the recent IQVIA report “Assessing the Biosimilar Void in the US” could be improved for the future.

Enhancing Biosimilar Adoption in Value-Based Oncology Care

February 16th 2025

By Travis Brewer

Video

Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for greater payer trust in oncologists’ treatment decisions.

Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD

February 15th 2025

By Deana Ferreri, PhD

Article

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.

Biosimilars Fuel Price Cuts in European Insulin Glargine Markets

February 14th 2025

By Skylar Jeremias

Article

Although Lantus continues to lead the insulin glargine market globally, the rise of biosimilars like Abasaglar and Semglee has sparked significant price reductions, with some European countries seeing discounts of up to 42.3%.

The Top 5 Biosimilar Articles for the Week of February 10

February 14th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of February 10, 2025.